JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on July 23, 2008; DOI: 10.1124/jpet.108.140897


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.108.140897v1
jpet.108.140897v2
327/1/239    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Bordia, T.
Right arrow Articles by Quik, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bordia, T.
Right arrow Articles by Quik, M.


Received for publication May 7, 2008.
Revised July 21, 2008.
Accepted for publication July 22, 2008.

Continuous and intermittent nicotine treatment reduces L-dopa-induced dyskinesias in a rat model of Parkinson's disease

Tanuja Bordia 1, Carla Campos 1, Luping Z. Huang 1, Maryka Quik 1*

1 The Parkinson's Institute

* Address correspondence to: E-mail: mquik{at}parkinsonsinstitute.org

Abstract

The development of abnormal involuntary movements (AIMs) or dyskinesias is a serious complication of L-dopa therapy for Parkinson's disease. Our previous work had shown that intermittent nicotine dosing reduced L-dopa-induced dyskinetic-like movements in nonhuman primates. A readily available nicotine formulation is the nicotine patch, which provides a constant source of nicotine. However, constant nicotine administration more readily desensitizes nicotinic receptors, to possibly yield alternate behavioral outcomes. We therefore investigated whether constant nicotine administration reduced L-dopa-induced AIMs in a rat parkinsonian model, with results compared to those with intermittent nicotine dosing. Rats with a unilateral 6-hydroxydopamine (6-OHDA) lesion were exposed to either intermittent (drinking water) or constant (minipump) nicotine for ≥2 wk at doses that yielded plasma levels of the nicotine metabolite cotinine similar to those in smokers. The rats were next treated with L-dopa/benserazide (8 or 12 mg/kg/15 mg/kg) for ≥3 wk to allow for the development of AIMs, with nicotine treatment continued. Both modes of nicotine administration resulted in ≥50% decline in L-dopa-induced AIMs. Nicotine treatment also significantly reduced AIMs in L-dopa primed rats using either dosing regimen, while nicotine removal led to an increase in AIMs. There was no effect of nicotine on various measures of motor performance in 6-OHDA-lesioned rats. In summary, nicotine provided either via the drinking water or minipump reduced L-dopa-induced AIMs in a rat model of Parkinson's disease. These results suggest that either intermittent or constant nicotine treatment may be useful in the treatment of L-dopa-induced dyskinesias in Parkinson's disease patients.


Key words: L-dopa, Parkinson's disease, dyskinesias, nicotine, nicotinic, nigrostriatal





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.